We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com
Archive for Pharmaceutical
Mar
02
Veeda Oncology is a vibrant Anglo/India CRO which brings together 20 years of clinical research expertise with the intellectual ability and tireless work ethic of the East. From First-in-Man studies to large scale Bioequivalence/Bioavailability comparator studies Veeda Clinical Research offers a fully integrated package to meet your early clinical development needs.
We provide phase 1 and phase II clinical trials and deliver cost effective research solutions for biotechnology oncology and pharmaceutical oncology. Veeda CR can take your compound from pre-clinical development to proof of concept in the most timely, cost effective manner.
Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research, which is a leading CRO specializing in the early clinical development of drugs with state of the art clinical pharmacology units in the UK, Europe and India, fully accredited GLP Laboratories and an established Biometrics team in Belgium and India.
Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service Oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.
Veeda Oncology is a full service CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure. Because of their geographic locations, the company is able to provide access to numerous clinical sites throughout the world resulting in greater access to patients with cancer and decreased time to study completion.
View our Oncology phase 1 trials,
Feb
18
Burke Pharmaceutical Research
Posted by: | Comments
Burke Pharmaceutical Research
Feb
07
Im looking for a position in regulatory affairs in pharmaceuticals in Toronto, and there are not many ads around. Does anybody here work in the industry who could give me some info on where is the best place to find ads?
Feb
01
This is what they don’t want the American people to know….
THE BAYH DOYLE ACT THE FIRST STEP TOWARDS COMMERCIALIZATION
This Act that Reagan introduced was intended to encourage the spreading of pharmaceutical education so that universities and the odd small business could patent the scientific discoveries from pharmaceutical research.
So, the public would pay for research that would ultimately serve the public’s health interest, in an industry that instantly became private. Our money then would now go to these big pharmaceutical companies instead of to improving the health of the American people.
The Bayh Doyle Act then has resulted in making the pharmaceuticals industry a $200 billion dollar industry every year. These are now the richest companies in the world.
And this has effectively changed the manner in which pharmaceutical education is disseminated. Now clinical trials are more biased than ever before, non-reporting of actual results is not happening, and the education behind real time data is being obscured and muddied. This is really happening people!
WHERE ARE YOUR DRUG DOLLARS GOING?
But wait, there is more. The government is behind all of it. In fact, the pharmaceutical industry is the largest lobbying body in Washington as we speak.
In 2002, the pharmaceutical industry employed almost 700 lobbyists, 26 of whom were former Congressmen, to lobby the government for higher costs in Medicare and more profits for the pharmaceutical industry.
That effort alone cost the taxpayers $91 million dollars alone, not to mention the challenges that the increased costs of Medicare incurred on the average American.
The corruption and scandal that lies behind the doors of the pharmaceutical industry is the education this country really needs, not the propaganda that we are paying for them to spit out.
I like to keep people informed of things like this, because the naysayers in this section work for and are paid by these same companies that try to keep us stupid. Their big money profits depend on keeping you and I in the dark.
We are taking back AMERICA! and not gonna take it anymore! You can believe that!
Hey Round 2, Little do you know that the pharmaceutical companies big money also finds it’s place in the lawyers pockets also. People need to open their eyes because I can see by comments like this that people just don’t KNOW!
Jan
19
Pharmaceutical Technologies and developments in Asia Pacific region
Posted by: | CommentsAsia Pacific Pharma Sector Analysis
The world continues to witness significant shift in the global pharmaceutical market landscape, with Asia-Pacific emerging as the fastest growing pharmaceutical market over the recent past. With low costs and favorable regulatory environment, the region has seen significant developments in the field of contract manufacturing, particularly in generics and APIs. Several technological advancements have also boosted the R&D activities in the region, helping the market to grow at double digit growth rate in recent years. The size of the Asia-Pacific pharma market is estimated at around US$ 187 Billion for 2009. ( http://www.bharatbook.com/detail.asp?id=125461&rt=Asia-Pacific-Pharma-Sector-Analysis.html )
According to our latest research report “Asia Pacific Pharma Sector Analysis”, the future of pharma industry in the Asia-Pacific region remains bright, and the industry is projected to grow at a CAGR of around 12.6% during 2010-2012. The growth will mainly be driven by low cost factors, changing regulatory environment and increased private sector investments in the industry. Currently, the market is characterized by high growth of generics, and the same trend will continue in near future also.
We have found that the region will become the global API production hub in next few years, backed by low cost manufacturing, favorable regulatory environment and current advancements in the production technology. Also, the market will show significant changes in terms of sales and marketing model, which will be changed into tender-based model, favoring the sales of low cost drugs, and thus resulting in intense competition among key players.
Our research reveals that the pharma sales are growing rapidly in countries like India, China, Malaysia, South Korea and Indonesia. This growth is mainly attributed to the increase in disposable income along with the emergence of several health insurance schemes, which are giving a boost to the sales of branded drugs. Besides this, the intense competition among key players in the region has been easing the availability of low cost drugs, thus providing a further boost to the market growth.
Our report provides an extensive and objective analysis on the Asia-Pacific pharma market. It provides analytical and statistical information on regional level markets, including their market size and segmentation. It also features an analysis on the future directions, supplemented with various facts and figures. Thus, the report serves as a useful guide for pharmaceutical companies, government officials, consultants and investors who are planning to enter the Asia-Pacific pharma market.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=125461&rt=Asia-Pacific-Pharma-Sector-Analysis.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook
Jan
19
Pharmaceutical Achievers: The Human Face of Pharmaceutical Research
Posted by: | Comments
Product Description
This biographical collection highlights individuals who made outstanding achievements in the arenas of pharmaceuticals and biotechnology. Pharmaceutical Achievers presents chronologically the major directions of pharmaceutical research and, in their historical context, the breakthroughs in treating various diseases. It concludes with a look at tomorrow’s medicines. This work is particularly useful in the classroom, where its accounts of challenges and triumphs may inspire students to consider careers that support pharmaceutical research and development.
Pharmaceutical Achievers: The Human Face of Pharmaceutical Research
Jan
02
Product Description
This super-accurate DigiWeigh DW-10PP Digital Scale is a well modeled and reliable weighing balance. With a capacity of 10 grams (50 carats or 154 grains), this scale is perfect for determining the weight of small items such as prescription pills, gold flakes or nuggets, lab chemical grams/ounces, loose diamond & gemstone carats, gunpowder grains, and more! This particular model includes a variety of accessories–including a REMOVABLE WEIGHING TRAY–all of which can be stored within the handsome box provided. Don’t forget about the LIFETIME WARRANTY. Plus, this scale is typically sold at $149.95! Don’t get ripped off—invest in your DigiWeigh DW-10PP today! I can also offer excellent deals on multiple orders… just contact me!
Genuine 10 x 0.001 Gram DIGITAL LAB BALANCE-Weigh Pharmaceutical Pill Press Tablets Scale PHARMACY TOOL Gift Idea!
Dec
27
A Look at Compulsory Licensing & Essential Medicines in the Pharmaceutical Industry
Posted by: | CommentsCompulsory licensing of essential medicines doesn’t always provide the greatest help to the poorest people of the world according to a round table highlighted by The Policy Network. The danger of compulsory licensing is that it can be abused by some in developing countries and create a culture of disrespect for intellectual property. The solution, rather than overt compulsory licensing, is to encourage these governments to respect intellectual property, thus creating incentives for the development of new medicines or technology. As mentioned by Dr.Bibek Debroy, Research Director at India’s Rajiv Gandhi Institute, when a property owner is allowed to protect his rights to the land, it provides him an incentive to develop and improve the land. Pharmaceutical intellectual property protection gives the developer the ability to finance the further advancement of that medicine. A compulsory license that is granted without sufficient cause dilutes the incentive for the developer of the medicine to improve the product.
How Compulsory Licensing Works
The concept of compulsory licensing for pharmaceuticals was originally developed to give the poorest countries in the world access to essential medicines in a time of crisis. For example, let’s say an African country is being overrun by an AIDS epidemic, but they can’t afford the brand name medications to be shipped overseas in the quantity they need. A compulsory license allows them to use the patent of the medication to manufacture it on their own so long as a royalty is paid to the intellectual property owner. However, the concept could be abused by pirates in developing countries to create generics of the drug with intent on capitalizing on a business opportunity.
The Intellectual Property Solution
Fortunately, a 2003 amendment to TRIP by the WTO to give the poorest countries alternatives to receiving the medicine they need has helped restore the concept of the compulsory license to its original intent. The amendment gives more oversight to making sure the medicines reach their intended destinations and are properly distributed as well as ensures that compulsory licenses are granted only to countries that do not have the means to develop their own medicines.
Pharmaceutical News 2.0 is run by James Wachai, a professional blogger. Each article highlighted on Pharmaceutical News 2.0 features one of several issues facing the pharmaceutical industry today. Topics include essential medicines, compulsory licensing, drug patents, essential medicines, biopiracy, and more.